 |
Advanced
Viral Research Corp. Announces Retention of James T. D'Olimpio,
MD As 'Spokesperson at Large'
YONKERS, N.Y., Nov. 18 /PRNewswire-FirstCall/ -- Advanced
Viral Research
Corp. (OTC Bulletin Board: ADVR) today announced the retention
of James T.
D'Olimpio M.D., as the Company's "Spokesperson at
Large." In this new role,
Dr. D'Olimpio will assist the Company in bridging the
information gap between
the investment community and the medical community in areas
surrounding the
further development and maturation of clinical trials of
AVR118 (formerly
known as Product R). In addition to this consulting role, Dr.
D'Olimpio will
continue as a member of the Company's Scientific Advisory
Board.
Eli Wilner, Chairman of the Company's Board said, "Jim
has assisted the
Company in the clinical development of AVR118, particularly
advising us on
matters pertaining to issues related to quality of life and
cachexia reversal.
Jim's new role, as a spokesman for the Company regarding the
potential use of
AVR118 in the treatment of cachexia, will strengthen our
ability to
communicate the findings coming from our Israeli clinical
trials to the
investment community and general public. We appreciate his
willingness to
accept these additional, consultative responsibilities. Jim
has an extensive
history in oncology research and treatment. His research
focuses primarily on
the areas of symptom control, palliative care, and cancer
cachexia."
Dr. D'Olimpio is the director of Supportive Oncology and the
Palliative
Care/Cancer Pain Service at North Shore University Hospital in
Manhasset, New
York. He also is an Assistant Professor of Medicine at the New
York
University School of Medicine. He is triple Board Certified in
the fields of
Internal Medicine, Medical Oncology and Hospice/Palliative
Medicine. Dr.
D'Olimpio has served on the ADVR Scientific Advisory Board
since February of
2001.
"The recent preliminary clinical results reported by the
Company from its
Israeli Phase I/II AIDS trial contain much encouraging raw
data," Dr.
D'Olimpio said. "It is of the utmost importance to
sustain the momentum by
increasing awareness of what Advanced Viral is trying to
accomplish in
furthering research of its technology platform in several
related disease
states."
D'Olimpio noted that there are many similarities in Quality of
Life Issues
and cachexia that are shared by patients with AIDS and cancer.
"Patients
suffer from cachexia in both diseases, and in fact, many
patients with AIDS
have co-existent cancers, making the situation even more
complex and
relevant."
As an author of multiple professional and technical papers,
Dr.
D'Olimpio's findings have appeared in exclusive journals such
as the Journal
of Clinical Oncology, Cancer Investigation, JAMA, American
Journal of Surgery,
Journal of Palliative Medicine and the Journal of Clinical
Pharmacology. He
is on the editorial staff of The Journal of Pain and Symptom
Management and
Cancer.
Dr. D'Olimpio is a member of several professional
organizations, including
the American Society of Clinical Oncology and the American
Academy of Hospice
and Palliative Medicine. He is also a member of the
Multi-National
Association for Supportive Care in Cancer (MASCC), where he is
a member of
their select cachexia research group, and the CALGB (Cancer
and Leukemia Group
B) where he sits on the symptom control committee. Dr.
D'Olimpio also was the
medical director for the Hospice Care Network Westbury, New
York. He has
lectured in related topics in symptom management throughout
the country and in
Europe and has appeared on CNN as a national expert in pain
control.
North Shore University Hospital is a major affiliate of the
North Shore -
Long Island Jewish Health System, and has recently been named
the "Number One
Hospital in America" by Modern Maturity Magazine, the
publication of the AARP
(American Association of Retired Persons).
ADVR's AVR118 represents a biopolymer chemistry that possesses
novel
immunomodulator activity. This peptide-nucleic acid, which to
date has shown
no indication of human toxicity, appears to stimulate the
proinflammatory
responses required to combat viral infections such as AIDS and
human papilloma
virus and to dampen aberrant autoimmune-type inflammatory
responses, such as
occur in patients with rheumatoid arthritis. Therefore, AVR118
has been
termed a "switch-type" immunomodulator. AVR118 is in
clinical trials in
Israel for the treatment of cachexia (body wasting) in
patients with AIDS.
For further information regarding Advanced Viral Research
Corp., please
visit our website at http://www.adviral.com
.
Advanced Viral Research Corp., based in Yonkers, New York, is
a
biopharmaceutical firm dedicated to improving patients' lives
by researching,
developing and bringing to market new and effective therapies
for viral and
other diseases.
Note: This news release contains forward-looking statements
that involve
risks associated with clinical development, regulatory
approvals, including
application to the FDA, product commercialization and other
risks described
from time to time in the SEC reports filed by the Company.
AVR118 (Product R)
is not approved by the U.S. Food and Drug Administration or
any comparable
agencies of any other countries. There is no assurance that
the Company will
be able to secure the financing necessary to continue and/or
complete the
clinical trials of AVR118 or satisfy certain other conditions
relating to
clinical trials including obtaining adequate insurance on
terms acceptable to
the Company or that if completed, clinical trials performed
outside the United
States will assist the Company in obtaining FDA or other
approval. The
Company undertakes no obligation to update or revise the
information contained
in this announcement whether as a result of new information,
future events or
circumstances or otherwise.
Contact:
Eli Wilner
914-376-7383
SOURCE Advanced Viral Research Corp.
Web site: http://www.adviral.com
Company News On-Call: http://www.prnewswire.com/comp/903002.html
(Voluntary Disclosure: Position- Long;
LT Rating- Strong Buy)
|
|
|
Keyboard shortcuts
Pressing these keys is the same as
clicking their link equivalents. Note: Netscape users don't have to
press enter after the shortcut. Mac users - use the CTRL key.
| Alt 1 [Enter] |
First unread |
| Alt Z [Enter] |
Previous or Older |
| Alt X [Enter] |
Next or Newer |
|
|
